25B-NBOMe (2-(4-bromo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine, also known as NBOMe-2C-B) is a synthetic psychedelic phenethylamine and structural analog of 2C-B, characterized by the addition of an N-(2-methoxybenzyl) group to the terminal amine. It is among the most potent serotonergic psychedelics ever identified, producing full psychedelic effects at doses as low as 250–750 μg. Like all NBOMe compounds, it is only active via sublingual or buccal routes.
25B-NBOMe is associated with multiple confirmed human fatalities, primarily resulting from acute vasoconstriction, hyperthermia, and seizures at high doses. The compound has an unusually narrow therapeutic window — the dose range between perceptible effect and dangerous toxicity is small. This danger is compounded by the fact that blotter potency varies significantly between batches and producers, making accurate dosing without quantitative chemical analysis impossible from a consumer perspective. Multiple death reports describe victims who ingested multiple blotters believing they were LSD.
The compound gained widespread forensic attention in the early 2010s when it appeared on blotter paper sold as LSD, prompting public health warnings from multiple national agencies. It does not produce the characteristic purple-violet color change with Ehrlich reagent (which detects indoles), making reagent testing an effective tool for distinguishing it from genuine LSD. Despite its dangers, it has been used recreationally for its intense visual and cognitive effects at sub-toxic doses by experienced users who carefully control dosing.
Safety at a Glance
High Risk- Ehrlich Reagent Test — Essential
- Additional testing with a Hofmann reagent (LSD turns blue) and/or sending a sample to EcstasyData.org or a similar ma...
- Toxicity: Confirmed Fatalities 25B-NBOMe has been directly linked to confirmed human fatalities. Deaths have resulted from acut...
- Dangerous with: Cocaine
- Overdose risk: fatal at heavy dosages. 25B-NBOMe has been used in clinical trials with an evaluation dose for sa...
If someone is in crisis, call 911 or Poison Control: 1-800-222-1222
Dosage
sublingual
insufflated
Duration
sublingual
Total: 8 hrs – 12 hrsinsufflated
Total: 4 hrs – 8 hrsHow It Feels
The onset is unmistakable and arrives with force. Within ten to fifteen minutes of sublingual or buccal administration, a powerful bitter numbness radiates through the mouth and gums. The body begins to vibrate with stimulant energy -- heart pounding, blood pressure climbing, a taut wiring of the muscles that feels like being plugged into a low-voltage current. The hands may tremble slightly, and a vasoconstriction tightens the extremities, making fingers and toes feel cold and distant. Colors in the environment begin to shift and intensify with startling speed.
By thirty to forty-five minutes, the visual effects have reached an extraordinary pitch. The world becomes a cathedral of geometry -- every surface alive with dense, rapidly shifting patterns of impossible complexity. Neon-bright fractals, spiraling mandalas, and tessellating grids overlay everything, pulsing in synchrony with the heartbeat. Edges of objects sprout elaborate filigree extensions. Colors are not merely saturated but seem to generate their own luminance, glowing from within like stained glass lit by an internal sun. The visual intensity of 25B-NBOMe at moderate doses exceeds what most classical psychedelics produce at any dose -- it is visual spectacle pushed to an almost overwhelming extreme.
The body load during the peak is significant and demands attention. Vasoconstriction produces a tightness in the chest and a cold, tingling sensation in the extremities. Nausea may come in waves. The jaw clenches persistently, and there is a restless compulsion to move, stretch, or pace. The stimulant energy is substantial -- sitting still can feel nearly impossible. The headspace, despite the visual pyrotechnics, remains surprisingly functional. Thought processes are accelerated and somewhat scattered but lack the ego dissolution or deep psychological excavation of substances like psilocybin or DMT. There is an emotional brightness, a giddy excitability, but it sits atop a physical discomfort that anchors the experience firmly in the body.
The peak sustains itself for two to three hours before gradually releasing its grip. The geometric overlays thin out and eventually dissipate, though color enhancement and visual shimmering persist well into the offset. The vasoconstriction and stimulant effects ease slowly -- the body unwinds over the course of several hours. Total duration spans six to ten hours. The aftermath typically includes fatigue, residual muscle tension, and occasionally a mild headache. There is rarely much of an afterglow in the warm, reflective sense that tryptamines provide -- instead, the feeling is more akin to having survived a brilliant, demanding storm.
Subjective Effects
The effects listed below are based on the Subjective Effect Index (SEI), an open research literature based on anecdotal reports and personal analyses. They should be viewed with a healthy degree of skepticism. These effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects.
Physical Effects
Physical(14)
- Body load— A diffuse, heavy physical discomfort involving tension, pressure, and malaise in the torso and limbs...
- Headache— A painful sensation of pressure, throbbing, or aching in the head that can range from a dull backgro...
- Increased heart rate— A noticeable acceleration of heartbeat that can range from a subtle awareness of one's pulse to a fo...
- Increased libido— A marked enhancement of sexual desire, arousal, and sensitivity to erotic stimuli that can range fro...
- Mouth numbing— Mouth numbing is a localized loss of sensation in the tongue, gums, cheeks, and surrounding oral tis...
- Muscle tension— Persistent partial contractions or tightening of muscles that produces uncomfortable stiffness, cram...
- Nausea— An uncomfortable sensation of queasiness and stomach discomfort that may or may not lead to vomiting...
- Perception of bodily lightness— Perception of bodily lightness is the subjective feeling that one's body has become dramatically lig...
- Physical euphoria— An intensely pleasurable bodily sensation that can manifest as waves of warmth, tingling electricity...
- Pupil dilation— A visible enlargement of the pupil diameter (mydriasis) that can range from subtle widening to drama...
- Seizure— Uncontrolled brain electrical activity causing convulsions and loss of consciousness -- a life-threa...
- Serotonin syndrome— Serotonin syndrome is a potentially fatal medical emergency caused by excessive serotonergic activit...
- Stimulation— A state of heightened physical and mental energy characterized by increased wakefulness, elevated mo...
- Vasoconstriction— A narrowing of blood vessels throughout the body that produces sensations of cold extremities, tingl...
Cognitive & Perceptual Effects
Visual(14)
- After images— A visual phenomenon in which a faint, ghostly imprint of a previously viewed image persists in the v...
- Colour enhancement— An intensification of the brightness, vividness, and saturation of colors in the external environmen...
- Colour shifting— The visual experience of colors on objects and surfaces cycling through continuous, fluid transforma...
- Drifting— The visual experience of perceiving stationary objects, textures, and surfaces as appearing to flow,...
- Geometry— The experience of perceiving complex, ever-shifting geometric patterns superimposed over the visual ...
- Internal hallucination— Vivid, detailed visual experiences perceived within an imagined mental landscape that can only be se...
- Pattern recognition enhancement— An increased ability and tendency to perceive meaningful patterns, faces, and images within ambiguou...
- Perspective hallucination— A hallucinatory phenomenon in which the observer's visual perspective shifts from the normal first-p...
- Scenery slicing— The visual field fractures into distinct, cleanly cut sections that slowly drift apart from their or...
- Settings, sceneries, and landscapes— The perceived environment in which hallucinatory experiences take place, ranging from recognizable l...
- Symmetrical texture repetition— Textures appear to mirror and tessellate across surfaces in intricate, self-similar symmetrical patt...
- Tracers— Moving objects leave visible trails of varying length and opacity behind them, similar to long-expos...
- Transformations— Objects and scenery undergo perceived visual metamorphosis, smoothly shapeshifting into other recogn...
- Visual acuity enhancement— Vision becomes sharper and more defined than normal, as though a slightly blurry lens has been broug...
Cognitive(12)
- Analysis enhancement— A perceived improvement in one's ability to logically deconstruct concepts, recognize patterns, and ...
- Anxiety— Intense feelings of apprehension, worry, and dread that can range from a subtle background unease to...
- Conceptual thinking— A shift in the nature of thought from verbal, linear sentence structures to intuitive, non-linguisti...
- Immersion enhancement— A heightened capacity to become fully absorbed and engrossed in external media such as music, films,...
- Introspection— An enhanced state of self-reflective awareness in which one feels drawn to examine their own thought...
- Memory suppression— A dose-dependent inhibition of one's ability to access and utilize short-term and long-term memory, ...
- Novelty enhancement— A feeling of increased fascination, awe, and childlike wonder attributed to everyday concepts, objec...
- Personal bias suppression— A decrease in the personal, cultural, and cognitive biases through which one normally filters their ...
- Thought acceleration— The experience of thoughts occurring at a dramatically increased rate, as if the mind has been shift...
- Thought connectivity— A state in which disparate thoughts, concepts, and ideas become fluidly and spontaneously interconne...
- Time distortion— Subjective perception of time becomes dramatically altered — minutes may feel like hours, or hours p...
- Wakefulness— An increased ability to stay awake and alert without the desire to sleep. Distinct from stimulation ...
Multi-sensory(1)
- Scenarios and plots— Scenarios and plots are the narrative structures that emerge within hallucinatory states — coherent ...
Transpersonal(1)
- Ego death— A profound dissolution of the sense of self in which personal identity, memories, and the boundary b...
Pharmacology
Mechanism of Action
25B-NBOMe acts as a highly potent partial agonist at serotonin 5-HT2A receptors, the canonical target of classical psychedelics. The addition of the N-(2-methoxybenzyl) group dramatically increases binding affinity at 5-HT2A — approximately 10–15 fold over the parent 2C-B compound. This is achieved through an additional hydrogen bond and hydrophobic interaction with the receptor binding pocket. The result is one of the highest known binding affinities for a synthetic 5-HT2A agonist.
Comparison with 2C-B
Relative to 2C-B (its parent compound), 25B-NBOMe is approximately 10–16 times more potent by dose. The subjective experience is broadly similar — intense visual distortion, perceptual enhancement, emotional amplification — but the NBOMe addition narrows the safety margin significantly. 2C-B at typical doses (15–25 mg) is considerably further from toxic territory than 25B-NBOMe at comparable effect intensity.
Additional Receptor Activity
Beyond 5-HT2A, 25B-NBOMe has affinity for 5-HT2C receptors (contributing to anxiogenic potential), and exerts alpha-adrenergic effects that produce the clinically significant vasoconstriction and cardiovascular stimulation associated with toxicity. It also has measurable activity at dopamine receptors, contributing to stimulant-like qualities at higher doses.
Pharmacokinetics
25B-NBOMe is inactive orally due to rapid first-pass metabolism. It is absorbed through oral mucosa following sublingual or buccal administration. Onset of effects occurs within 20–45 minutes, with peak effects at 2–3 hours and total duration of 5–8 hours. The compound is highly lipophilic, crosses the blood-brain barrier efficiently, and is metabolized by hepatic CYP450 enzymes. Detailed human pharmacokinetic data are not available from controlled clinical studies.
Tolerance
Rapid functional tolerance develops with repeated use, likely via 5-HT2A receptor downregulation. Cross-tolerance with LSD, psilocybin, mescaline, and other serotonergic psychedelics is expected. A minimum of 5–7 days between uses is recommended.
Detection Methods
Urine Detection
25B-NBOMe is not targeted by standard immunoassay-based urine drug screens. However, due to its phenethylamine backbone, there is a theoretical possibility of cross-reactivity with amphetamine immunoassays, though this has not been consistently reported in clinical literature. Specialized LC-MS/MS methods developed for novel psychoactive substances can detect NBOMe compounds and their metabolites in urine for approximately 24 to 48 hours after ingestion, depending on dose and individual metabolism.
Blood and Serum Detection
Blood detection windows for 25B-NBOMe are relatively short. Peak plasma concentrations occur within 30 minutes to 2 hours depending on the route of administration (sublingual absorption is typical for NBOMe compounds). Blood concentrations fall below detectable thresholds within 6 to 16 hours for most methods. LC-MS/MS remains the only reliable analytical approach for serum detection, as the doses involved (typically hundreds of micrograms to low milligrams) produce low absolute concentrations.
Standard Drug Panel Inclusion
25B-NBOMe is NOT included on standard 5-panel, 10-panel, or 12-panel drug screens. It is not specifically targeted by any routine workplace or clinical immunoassay. While some structural similarity to amphetamines exists, cross-reactivity on amphetamine panels is inconsistent and cannot be relied upon for either detection or exclusion. Identification requires specific testing at a reference laboratory equipped for novel psychoactive substance analysis.
Confirmatory Methods
Definitive identification of 25B-NBOMe requires LC-MS/MS or high-resolution mass spectrometry (HRMS). GC-MS can also be employed but may require derivatization due to the thermal lability of NBOMe compounds. Reference standards are necessary for quantitative confirmation. Forensic and clinical toxicology laboratories that maintain novel psychoactive substance panels are the only facilities reliably capable of this analysis.
Reagent Testing (Harm Reduction)
Reagent testing is critically important for NBOMe compounds due to their significantly higher toxicity profile compared to classical psychedelics. The Ehrlich reagent shows NO reaction with 25B-NBOMe, which is the single most important distinguishing test: any substance sold as a psychedelic that fails to turn purple with Ehrlich may be an NBOMe compound rather than LSD or a tryptamine. The Marquis reagent produces variable results depending on the specific NBOMe compound, ranging from no reaction to green or brown color changes. The Mecke reagent may produce a brown or dark green reaction. For harm reduction purposes, always testing with Ehrlich first is essential. The absence of a purple Ehrlich reaction is a strong warning sign that the substance is not a lysergamide or tryptamine and may be a potentially dangerous NBOMe compound.
Interactions
| Substance | Status | Note |
|---|---|---|
| Cocaine | Unsafe | — |
| 3-FMA | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| 4-MMC | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| 8-Chlorotheophylline | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| Adrafinil | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| Anandamide | Caution | Cannabis can unpredictably intensify psychedelic effects and increase anxiety |
| 2C-T-x | Uncertain | — |
| Caffeine | Uncertain | — |
| Cannabis | Uncertain | — |
| DOx | Uncertain | — |
| MDMA | Uncertain | — |
History
Synthesis and Research Origins
25B-NBOMe was first synthesized in 2004 by Ralf Heim at the Free University of Berlin, as part of a doctoral dissertation investigating the pharmacology of N-benzylphenethylamine derivatives. The research demonstrated that the addition of an N-(2-methoxybenzyl) group to phenethylamine psychedelics dramatically increased their affinity for 5-HT2A receptors. The compound was subsequently characterized in detail by David Nichols' group at Purdue University, where it was used as a pharmacological tool to probe 5-HT2A receptor function.
Emergence in Drug Markets
25B-NBOMe entered recreational drug markets in the early 2010s alongside 25I-NBOMe and 25C-NBOMe, primarily distributed on blotter paper. The blotter format and sublingual administration created dangerous surface similarity to LSD, and the compounds were widely sold as LSD to users with no means to distinguish them.
Public Health Response
The surge of NBOMe-related hospitalizations and fatalities in 2012–2015 prompted emergency scheduling actions from the US DEA (2013), UK Advisory Council on the Misuse of Drugs, and multiple European nations. The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) issued alerts documenting deaths across multiple countries. Forensic databases from this period are heavily populated with NBOMe identifications.
Current Status
25B-NBOMe is Schedule I in the United States (scheduled 2013), Class A in the UK, and controlled in most EU member states. Forensic prevalence has declined from the 2012–2015 peak but remains a documented phenomenon in drug checking databases worldwide.
Harm Reduction
Ehrlich Reagent Test — Essential
The single most important harm reduction action for anyone who suspects they have LSD blotter is to test it with an Ehrlich reagent. LSD produces a distinctive purple-violet color change. 25B-NBOMe contains no indole ring and producesno color change with Ehrlich. A negative Ehrlich test on material presented as LSD is a strong indicator of a non-indole compound, including NBOMe.
Additional testing with a Hofmann reagent (LSD turns blue) and/or sending a sample to EcstasyData.org or a similar mass spectrometry service provides definitive identification.
Sublingual Administration Only
25B-NBOMe is inactive when swallowed and must be administered sublingually or buccally. Place the blotter under the tongue or inside the cheek and hold it there for 15–20 minutes. Do not eat or drink acidic beverages in the period immediately before or during absorption.
Do Not Redose
The slow onset — up to 45 minutes — is the primary driver of accidental overdose with NBOMe compounds. Redosing before the first dose takes effect has caused numerous serious adverse events and deaths. If effects have not appeared within 60 minutes, the dose may be inactive for physiological reasons (not because "it isn't working") — do not add more.
Dose Ranges and Risks
- Threshold: ~200–400 μg (individual blotters commonly contain 500–1,000 μg)
- Common: 500–750 μg
- Strong: 750–1,200 μg — elevated physiological risk
- High: 1,200+ μg — significant risk of toxicity
Without quantitative testing, the dose in any given blotter is unknown. Experienced users recommend biting off a fraction of a blotter on first exposure and waiting the full onset period before considering any additional dose.
Monitor for Vasoconstriction Warning Signs
- Pale, blue, or cold fingers, toes, or lips
- Chest tightness or chest pain
- Difficulty breathing
- Pronounced numbness in extremities
Any of these during an experience should be treated as a medical alert. Get to a warm environment, cease any physical exertion, call emergency services if symptoms are severe or progressing.
Emergency Response
- Call emergency services if: seizure, chest pain, loss of consciousness, blue or cold extremities that do not improve, extreme hyperthermia
- Benzodiazepines are the appropriate pharmacological intervention for agitation and anxiety
- Inform emergency services of the substance taken — treatment will differ from standard MDMA or alcohol toxicity
Toxicity & Safety
Confirmed Fatalities
25B-NBOMe has been directly linked to confirmed human fatalities. Deaths have resulted from acute cardiovascular collapse, hyperthermia, seizures, and rhabdomyolysis, often in the context of high-dose ingestion. Multiple fatalities have also occurred when the compound was sold as LSD, with victims consuming multiple blotters under the mistaken belief that they were taking a substantially safer drug.
Vasoconstriction — Primary Mechanism of Toxicity
The most clinically significant acute risk of 25B-NBOMe is severe vasoconstriction via alpha-adrenergic receptor activation. At high doses, this can progress from peripheral symptoms (cold, blue extremities) to systemic vascular compromise, cardiac ischemia, and cardiovascular collapse. Risk is dramatically elevated by concurrent stimulant use. Case reports describe peripheral gangrene, acute coronary syndrome, and multi-organ failure following high-dose NBOMe toxicity.
Hyperthermia
Dangerous elevations in core body temperature are a consistent feature of severe NBOMe toxicity. Physical activity (dancing) dramatically exacerbates temperature rise. Combined with the stimulant-like profile of NBOMe compounds, hyperthermia has been a contributing factor in multiple fatalities.
Seizures
Tonic-clonic seizures occur in severe NBOMe toxicity and have been documented in fatal cases. The seizure threshold appears to be lowered by the compound; combination with lithium or tramadol represents an absolute contraindication.
Narrow Therapeutic Window
The dose range between a psychedelic effect and a potentially dangerous physiological response is narrow with 25B-NBOMe. Factors including body weight, CYP450 genetic polymorphisms, tolerance state, and blotter-to-blotter potency variation all affect where a given user falls within that window. This is a fundamental property of the compound, not an artifact of improper use.
Drug Interactions
- Stimulants — Absolutely contraindicated; compound vasoconstriction and cardiac risk
- Lithium — Absolutely contraindicated; seizures and cardiac events
- MAOIs — Avoid; serotonin syndrome risk
- Cannabis — Unpredictably amplifies intensity; has contributed to adverse events
- Other vasoconstrictors — Compounded risk
Contraindications
- Cardiovascular disease, hypertension, or vascular disorders (absolute contraindication)
- Personal or family history of schizophrenia or bipolar disorder
- Concurrent stimulant use
- Concurrent lithium or MAOI use
Addiction Potential
not habit-forming
Overdose Information
fatal at heavy dosages.
25B-NBOMe has been used in clinical trials with an evaluation dose for safety consideration to humans of only 1 microgram; Such a dose is 300× lower than the dose expected to be hallucinogenic to humans and it is expected that recreational use would greatly exceed doses determined to be safe to humans.
It is strongly recommended that one use harm reduction practices when using this substance.
25B-not habit-forming, and the desire to use it can actually decrease with use. It is most often self-regulating.
Tolerance to the effects of 25B-almost immediately after ingestion. After that,12 weeks to be back at baseline (in the absence of further consumption). 25B-NBOMe presents cross-tolerance with Cross-all psychedelics, meaning that after the consumption of 25B-NBOMe all psychedelics will have a reduced effect.
Overdose
Austria: Since June 26, 2019, 25B-NBOMe is illegal to possess, produce and sell under the SMG. (Suchtmittelgesetz Österreich)
Brazil: Possession, production and sale is illegal as it is listed on Portaria SVS/MS nº 344.
Canada: 25B-NBOMe would be considered Schedule III as it is a derivative of 2,5-dimethoxyphenethylamine.
China: As of October 2015, 25B-NBOMe is a controlled substance in China.
Germany: 25B-NBOMe is controlled under Anlage I BtMG (Narcotics Act, Schedule I) as of December 13, 2014. It is illegal to manufacture, possess, import, export, buy, sell, procure or dispense it without a license.
Italy: 25B-NBOMe is a Schedule 1 controlled substance in Italy.
Japan: 25B-NBOMe is a narcotic drug in Japan effective November 1st, 2015.
Latvia: 25B-NBOMe is a Schedule I controlled substance.
New Zealand: 25B-NBOMe is a
Dangerous Interactions
The combinations listed below may be life-threatening. Independent research should always be conducted to ensure safety when combining substances.
Tolerance
| Full | almost immediately after ingestion |
| Half | 1 week |
| Zero | 2 weeks |
Cross-tolerances
Legal Status
Austria: Since June 26, 2019, 25B-NBOMe is illegal to possess, produce and sell under the SMG. (Suchtmittelgesetz Österreich)
Brazil: Possession, production and sale is illegal as it is listed on Portaria SVS/MS nº 344.
Canada: 25B-NBOMe would be considered Schedule III as it is a derivative of 2,5-dimethoxyphenethylamine.
China: As of October 2015, 25B-NBOMe is a controlled substance in China.
Germany: 25B-NBOMe is controlled under Anlage I BtMG (Narcotics Act, Schedule I) as of December 13, 2014. It is illegal to manufacture, possess, import, export, buy, sell, procure or dispense it without a license.
Italy: 25B-NBOMe is a Schedule 1 controlled substance in Italy.
Japan: 25B-NBOMe is a narcotic drug in Japan effective November 1st, 2015.
Latvia: 25B-NBOMe is a Schedule I controlled substance.
New Zealand: 25B-NBOMe is a Schedule 2 controlled substance in New Zealand.
Sweden: 25B-NBOMe is classed as Schedule I.
Switzerland: 25B-NBOMe is a controlled substance specifically named under Verzeichnis D.
Turkey:** 25B-NBOMe is a classed as drug and is illegal to possess, produce, supply, or import.
United Kingdom: 25B-NBOMe is a Class A drug in the United Kingdom as a result of the N-benzylphenethylamine catch-all clause.
United States: On Nov 15, 2013, the DEA added 25B-NBOMe to Schedule I using their emergency scheduling powers, making it "temporarily" in Schedule I for 2 years.
Responsible use
Research chemical
Psychedelics
Phenethylamines
25B-NBOMe (Wikipedia)
25B-NBOMe (Isomer Design)
25B-NBOMe (Disregard Everything I say)
Experience Reports (1)
Tips (8)
Have a trip sitter present, ideally someone with psychedelic experience. They should remain calm and reassuring without being intrusive. A good sitter can make the difference between a challenging experience and a genuine crisis.
Do not combine 25B-NBOMe with lithium (seizure risk), tramadol (seizure/serotonin syndrome risk), or cannabis at higher doses unless very experienced. Cannabis dramatically intensifies and can destabilize a psychedelic experience.
25B-NBOMe is sometimes sold on blotters as LSD. It has a distinctly bitter and metallic taste that numbs the tongue, which real LSD does not have. Always use an Ehrlich reagent test before consuming any blotter. If it is bitter, spit it out.
25B-NBOMe has been linked to at least one confirmed fatality of a 17-year-old. Never insufflate this compound, as the extreme potency makes nasal dosing dangerously imprecise. Sublingual or buccal routes with accurately laid blotters are the only acceptable methods.
Keep a benzodiazepine like alprazolam on hand as an emergency trip abort tool when using 25B-NBOMe. Even just knowing you have one available provides psychological reassurance. It will not fully end the trip but significantly reduces intensity.
Clear your schedule for the full duration of 25B-NBOMe plus afterglow. Do not plan any obligations, driving, or important decisions for the day. Having a time pressure or commitment hanging over you adds unnecessary anxiety.
Community Discussions (1)
See Also
References (4)
- Psilocybin produces substantial and sustained decreases in depression and anxiety — Griffiths et al. Journal of Psychopharmacology (2016)paper
- Neural correlates of the LSD experience revealed by multimodal neuroimaging — Carhart-Harris et al. PNAS (2016)paper
- 25B-NBOMe - TripSit Factsheet
TripSit factsheet for 25B-NBOMe
tripsit - 25B-NBOMe - Wikipedia
Wikipedia article on 25B-NBOMe
wikipedia